Andrés López

GEMOX‐R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large‐cell lymphoma: a phase II study

Andrés López, Antonio Gutiérrez, Andrés Palacios et al. · European Journal Of Haematology · 2007 · 110 citations

A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy

Marek Trněný, Gregor Verhoef, Martin J.S. Dyer et al. · Haematologica · 2018 · 60 citations · Full text

Long‐term follow‐up of dose‐adjusted EPOCH plus rituximab (DA‐EPOCH‐R) in untreated patients with poor prognosis large B‐cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group

Noelia Purroy, Juan Bergua, Laura Gallur et al. · British Journal of Haematology · 2014 · 56 citations · Full text

Autologous stem cell transplantation for primary refractory Hodgkin’s disease: results and clinical variables affecting outcome

M. Constans, Anna Sureda, María José Terol et al. · Annals of Oncology · 2003 · 46 citations

Regenerative Medicine, Cell Therapy, Transplantation +8

Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain

José Mayordomo, Andrés López, Núria Viñolas et al. · Current Medical Research and Opinion · 2009 · 45 citations